These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 19578136

  • 1. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate.
    Amital H, Arnson Y, Chodick G, Shalev V.
    Rheumatology (Oxford); 2009 Sep; 48(9):1107-10. PubMed ID: 19578136
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study.
    Hakamata J, Hashiguchi M, Kaneko Y, Yamaoka K, Shimizu M, Maruyama J, Takeuchi T, Mochizuki M.
    Mod Rheumatol; 2018 Jul; 28(4):611-620. PubMed ID: 29252093
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
    Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS.
    J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
    [Abstract] [Full Text] [Related]

  • 7. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study.
    Verstappen SM, Bakker MF, Heurkens AH, van der Veen MJ, Kruize AA, Geurts MA, Bijlsma JW, Jacobs JW, Utrecht Rheumatoid Arthritis Cohort Study Group.
    Ann Rheum Dis; 2010 Jun; 69(6):1044-8. PubMed ID: 19581281
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of low dose methotrexate on bone density.
    Cranney AB, McKendry RJ, Wells GA, Ooi DS, Kanigsberg ND, Kraag GR, Smith CD.
    J Rheumatol; 2001 Nov; 28(11):2395-9. PubMed ID: 11708409
    [Abstract] [Full Text] [Related]

  • 10. Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study.
    Seitz M, Reichenbach S, Möller B, Zwahlen M, Villiger PM, Dufour JF.
    Ann Rheum Dis; 2010 Jun; 69(6):1148-50. PubMed ID: 19854710
    [Abstract] [Full Text] [Related]

  • 11. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
    Chen YJ, Chang YT, Shen JL, Chen TT, Wang CB, Chen CM, Wu CY.
    Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
    [Abstract] [Full Text] [Related]

  • 12. Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by Fibroscan in rheumatoid arthritis patients receiving methotrexate.
    Lertnawapan R, Chonprasertsuk S, Siramolpiwat S.
    Int J Rheum Dis; 2019 Feb; 22(2):214-221. PubMed ID: 30565876
    [Abstract] [Full Text] [Related]

  • 13. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I, Koó E, Seszták M, Gergely P.
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB, von Kempis J, Haile SR, Schiff MH.
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [Abstract] [Full Text] [Related]

  • 15. Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.
    Dávila-Fajardo CL, Swen JJ, Cabeza Barrera J, Guchelaar HJ.
    Pharmacogenomics; 2013 Jan; 14(1):63-73. PubMed ID: 23252949
    [Abstract] [Full Text] [Related]

  • 16. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
    Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A.
    Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
    [Abstract] [Full Text] [Related]

  • 17. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients.
    Wollina U, Ständer K, Barta U.
    Clin Rheumatol; 2001 May; 20(6):406-10. PubMed ID: 11771523
    [Abstract] [Full Text] [Related]

  • 18. Adverse effects of low dose methotrexate in rheumatoid arthritis patients.
    Gilani ST, Khan DA, Khan FA, Ahmed M.
    J Coll Physicians Surg Pak; 2012 Feb; 22(2):101-4. PubMed ID: 22313647
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.
    Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C.
    Clin Rheumatol; 1997 May; 16(3):296-304. PubMed ID: 9184269
    [Abstract] [Full Text] [Related]

  • 20. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study.
    Attar SM.
    Saudi Med J; 2010 Aug; 31(8):909-15. PubMed ID: 20714691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.